Cancers, including those incurable ones, can be treated with a bispecific antibody by allowing T cells to attack the treatment-resistant cancers, scientists claimed. According to Medical Express, since there are too many tumors that do not respond to immunotherapy, it remains an imperfect medical tool. 

This problem might be solved by an evolving class of engineered proteins called "bispecific' antibodies. This antibody is named after the dual recognition capability and can bind to the surface antigen of a cancer cell itself. It is also engineered to home in on a T cell surface receptor. The results of the study were published in Science Mag.

Also Read: [BEWARE] Coronavirus May Still Linger in Recovered Patients' Hearts for Months Without Any Symptoms

Its main goal is to activate T cell's tumor annihilating capability and bring two types of cells together. The Regeneron Pharmaceuticals, a leading biotechnology company, located in Tarrytown, New York, is currently studying the bispecific antibodies. 

Also Read: COVID-19 Vaccine: China Leads the Race But Might Have Issues as They Enter Phase 3 of Trials; Here's Why

The company's REGN-EB3, a triple antibody cocktail, outperformed other experimental treatment last year for Ebola, because of its promising development. It is currently being reviewed by the United States Food and Drug Administration (FDA), expecting it to receive full approval this year. Regeneron scientists are currently studying an antibody-based treatment for the novel coronavirus.

How bispecific antibodies work

The report also confirmed that Regeneron's bispecific antibodies have grown out of a sobering reality since there are some cancers that developed deceptive strategies that give them the ability to resist immunotherapy. To overcome cancer's evolution, the investigational bispecific antibodies were designed to overcome cancer-cell resistance.

Dimitris Skokos and Janelle Waite, the scientists who are part of a large Regeneron team, made advancement in testing a class of co-stimulatory CD28-bispecific antibodies. Since the checkpoint blockade immunotherapy relies on drugs known as immune checkpoint inhibitors, it is already considered as an innovative form of cancer therapy.The scientists designed it to engage the body's T cells to treat multiple forms of cancer, by recognizing and attacking malignant cells.

Also Read: COVID-19: Children Ages 5 and Below May Carry Virus 10 to 100 Times More

This article is owned by TechTimes,

Written by: Giuliano de Leon.

ⓒ 2021 TECHTIMES.com All rights reserved. Do not reproduce without permission.